Abstract
This Practice Point commentary discusses the findings of the first phase I trial to evaluate abiraterone acetate (an inhibitor of the androgen-regulating enzyme CYP17) in the treatment of castration-resistant prostate cancer. This open-label, dose-escalation study by Attard et al. showed that abiraterone was well tolerated but often induced a syndrome of secondary mineralocorticoid excess that improved with eplerenone (a mineralocorticoid receptor antagonist). Abiraterone is a potent suppressor of adrenal androgen synthesis, and produced lasting prostate-specific antigen responses in approximately half of the patients. A few patients had partial regression of distant metastases. Although promising, these results should be interpreted with caution owing to the small sample size and because the study was not primarily designed to examine drug efficacy. Multi-institutional, prospective trials should provide additional information on the tolerability and activity of this compound and further define the population most likely to benefit from this endocrine approach.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Attard G et al. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26: 4563–4571
Mostaghel EA et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033–5041
Stigliano A et al. (2007) Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 194: 55–61
Ryan CJ and Eisenberger MA (2005) Chemotherapy for hormone-refractory prostate cancer: now it's a question of “when?” J Clin Oncol 23: 8242–8246
Ryan CJ et al. (2008) Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17α-hydroxylase C17,20-lyase inhibitor, in castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 26: 5018
De Bono JS et al. (2008) Antitumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy-naive and docetaxel pretreated castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 26: 5005
Danila DC et al. (2008) Abiraterone acetate and prednisone in patients with progressive metastatic castration-resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy [abstract]. J Clin Oncol 26: 5019
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Antonarakis, E., Eisenberger, M. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?. Nat Rev Clin Oncol 6, 12–13 (2009). https://doi.org/10.1038/ncponc1262
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1262
This article is cited by
-
Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review
World Journal of Urology (2020)
-
Breast and prostate cancer: more similar than different
Nature Reviews Cancer (2010)